NCT04416646 2024-02-21
ZEBRA
Istituto Oncologico Veneto IRCCS
Unknown
Clinical Trials
7 trialsNCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02041260 2021-10-15
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Thomas Jefferson University
Phase 2 Unknown
NCT04427787 2021-09-05
LOLA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04714697 2021-01-19
Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
Asan Medical Center
Phase 2 Unknown
NCT04435977 2020-06-17
Immunocabo
Istituto Clinico Humanitas
Phase 2 Unknown
NCT03911193 2019-04-11
CABinMET
Fondazione Ricerca Traslazionale
Phase 2 Unknown